new_0222_0720|CMMB|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0720|CMMB|1|Chemomab Therapeutics Ltd Total Current Assets (Quarterly) (USD)|Chemomab Therapeutics Ltd Cash and Short Term Investments (Quarterly) (USD)|Chemomab Therapeutics Ltd Inventories (Quarterly) (USD)|Chemomab Therapeutics Ltd Net PP&E (Quarterly) (USD)|Chemomab Therapeutics Ltd Goodwill and Intangibles (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Liabilities (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Current Liabilities (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Long Term Liabilities (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Deposits (Quarterly) (USD)|Chemomab Therapeutics Ltd Book Value (Quarterly) (USD)|Chemomab Therapeutics Ltd Retained Earnings (Quarterly) (USD)|Chemomab Therapeutics Ltd Treasury Stock (Quarterly) (USD)|Chemomab Therapeutics Ltd EV to Revenues|Chemomab Therapeutics Ltd EV to Earnings|Chemomab Therapeutics Ltd EV to Free Cash Flow|Chemomab Therapeutics Ltd EV to Assets (Quarterly)|Chemomab Therapeutics Ltd PS Ratio|Chemomab Therapeutics Ltd PE Ratio|Chemomab Therapeutics Ltd Price to Book Value|Chemomab Therapeutics Ltd PEG Ratio|Chemomab Therapeutics Ltd Debt to Equity Ratio|Chemomab Therapeutics Ltd Dividend Yield|Chemomab Therapeutics Ltd Shareholder Yield (TTM)|Chemomab Therapeutics Ltd Percent of Shares Outstanding Short|Chemomab Therapeutics Ltd Total Receivables (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Payables (Quarterly) (USD)|Chemomab Therapeutics Ltd Total Capital Stock (Quarterly) (USD)|Chemomab Therapeutics Ltd Return on Invested Capital|Chemomab Therapeutics Ltd Quality Ratio Score|Chemomab Therapeutics Ltd Momentum Score|Chemomab Therapeutics Ltd Beta (1Y)|Chemomab Therapeutics Ltd Sustainable Growth Rate (TTM)|Chemomab Therapeutics Ltd Institutional Investor Ownership Percentage|Chemomab Therapeutics Ltd Average Diluted Shares Outstanding (Quarterly)|Chemomab Therapeutics Ltd Total Employees (Annual)|Chemomab Therapeutics Ltd EPS Diluted (Quarterly) (USD)|Chemomab Therapeutics Ltd SG&A Expense (Quarterly) (USD)|Chemomab Therapeutics Ltd Shares Outstanding|Chemomab Therapeutics Ltd Repurchase of Capital Stock (Quarterly) (USD)|Chemomab Therapeutics Ltd Ordinary Shares Number (Quarterly)|Chemomab Therapeutics Ltd Payout Ratio|Chemomab Therapeutics Ltd Quick Ratio (Quarterly)|Chemomab Therapeutics Ltd Normalized Diluted EPS (Quarterly) (USD)|Chemomab Therapeutics Ltd Stock Buybacks (Quarterly) (USD)|Chemomab Therapeutics Ltd Effective Tax Rate (TTM)|Chemomab Therapeutics Ltd Return on Equity|Chemomab Therapeutics Ltd Net Income (TTM) (USD)|Chemomab Therapeutics Ltd Revenue (TTM) (USD)|Chemomab Therapeutics Ltd Dividend Per Share (Quarterly) (USD)|Chemomab Therapeutics Ltd Revenue (Quarterly) (USD)|Chemomab Therapeutics Ltd Gross Profit (Quarterly) (USD)|Chemomab Therapeutics Ltd Pre-Tax Income (Quarterly) (USD)|Chemomab Therapeutics Ltd Net Income (Quarterly) (USD)|Chemomab Therapeutics Ltd Net Interest Income (Quarterly) (USD)|Chemomab Therapeutics Ltd Price (USD)|Chemomab Therapeutics Ltd Total Return Price (USD)|Chemomab Therapeutics Ltd Enterprise Value (USD)|Chemomab Therapeutics Ltd 30-Day Average Daily Volume|Chemomab Therapeutics Ltd 1 Year Price Returns (Daily)|Chemomab Therapeutics Ltd Short Interest|Chemomab Therapeutics Ltd PE Ratio (Forward)|Chemomab Therapeutics Ltd PE Ratio (Forward 1y)|Chemomab Therapeutics Ltd PS Ratio (Forward)|Chemomab Therapeutics Ltd PS Ratio (Forward 1y)|Chemomab Therapeutics Ltd Quarterly EPS Estimates (USD)|Chemomab Therapeutics Ltd Quarterly Revenue Estimates (USD)|Chemomab Therapeutics Ltd Quarterly EPS Surprise|Chemomab Therapeutics Ltd Quarterly Revenue Surprise|Chemomab Therapeutics Ltd Quarterly Actual EPS (USD)|Chemomab Therapeutics Ltd Quarterly Actual Revenue (USD)|Chemomab Therapeutics Ltd Revenue Estimates for Current Fiscal Year (USD)|Chemomab Therapeutics Ltd Revenue Estimates for Next Fiscal Year (USD)|Chemomab Therapeutics Ltd Price Target (USD)|Chemomab Therapeutics Ltd Consensus Recommendation|Chemomab Therapeutics Ltd Price Target Num Estimates|Chemomab Therapeutics Ltd EPS Estimates for Current Fiscal Year (USD)|Chemomab Therapeutics Ltd EPS Estimates for Next Fiscal Year (USD)|Chemomab Therapeutics Ltd Research and Development Expense (Quarterly) (USD)|Chemomab Therapeutics Ltd Reconciled Depreciation (Quarterly) (USD)|Chemomab Therapeutics Ltd Non-Operating Interest Expense (Quarterly) (USD)|Chemomab Therapeutics Ltd Land and Improvements (Quarterly) (USD)|Chemomab Therapeutics Ltd Buildings and Improvements (Quarterly) (USD)|Chemomab Therapeutics Ltd Other Properties (Quarterly) (USD)|Chemomab Therapeutics Ltd Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0720|CMMB|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0720|CMMB|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0720|CMMB|5|91.5|91.5||91.5||91.5|91.5|91.5||91.5|91.5||||1.43103448276||||1.43103448276|||1.44619422572||15.3333333333|91.5|91.5|91.5|||31.9523809524|30.5217391304||30.7142857143|109.6||109.6|109.6|37.75||91.5|||109.6|109.6|||91.5|||||109.6|109.6|109.6|6.9746835443|6.9746835443|1.43103448276|6.97368421053|1.44509803922|15.4117647059|||||91.5|91.4285714286|92||92|91.5|21|22.9090909091|18|14|18|22.3636363636|22.9090909091|109.6|109.6||||91.5|||
new_0222_0720|CMMB|6|2|2||2||2|2|2||2|2||||174||||174|||762||15|2|2|2|||21|23||7|5||5|5|4||2|||5|5|||2|||||5|5|5|158|158|174|152|510|17|||||6|7|1||1|2|12|11|14|18|14|11|11|5|5||||2|||
new_0222_0720|CMMB|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0720|CMMB|201812|||||||||||||||||||||||||||||||||||||||||||||||||||||||131.2|131.2||||||||||||||||||||||||||||||
new_0222_0720|CMMB|201903|||||||||||||||||||||||||||||||||||||||||||||||||||||||108|108||41740.5667|||||||||||||||||||||||||||93.2|76.7264
new_0222_0720|CMMB|201906|||||||||||||||||||||||||||||||||||||||||||||||||||||||68|68||5100.4333|||||||||||||||||||||||||||50.48|36.6384
new_0222_0720|CMMB|201909|||||||||||||||||||||||||||||||||||||||||||||||||||||||42.56|42.56||57584.4|||||||||||||||||||||||||||35.52|21.2192
new_0222_0720|CMMB|201912|||||||||||||||||||||||||||||||0.6736||||||||||||||||||||||||22.4|22.4||36354.9667|-88.7688||||||||||||||||||||||||||21.6|19.5872
new_0222_0720|CMMB|202003||||||||||||||||||||||||||||||1|0.2754|||11.0029||-0.154|0.152||||||-0.154|||||||||-1.695|-1.695|0.009|12.576|12.576||25592.3667|-88.4327|||||||||||||||||||1.552|0.005||||||12.8|18.24
new_0222_0720|CMMB|202006||||||||||||||||||||||||||||||1|1.4254|||11.0029||-0.0982|0.254||||||-0.0982|-3||||||||-1.081|-1.081|0.02|21.92|21.92||93399.1|-69.4196|||||||||||||||||||0.847|0.005||||||14.528|16.8
new_0222_0720|CMMB|202009||||||||||||||||||||||||||||||2|0.8363|||11.0029||-0.1112|0.194||||||-0.1112|||||||||-1.224|-1.224|0.001|19.04|19.04||50909.8333|-50.4197|||||||||||||||||||1.031|0.008||||||18.88|24
new_0222_0720|CMMB|202012||||||||||||||||||||||||||||||7|1.0977||||||||||||||||||||||||32|32||3341300.2667|23.5714||||||||||||||||||||||||||38.24|60.16
new_0222_0720|CMMB|202103|59.523|58.203||0.545||4.959|4.631|0.328||55.164|-25.399||||||||||||||0.32|2.083||||9|-0.8276|||7.8376||-0.22|0.542|||227.9561|||-0.22|-45.372|||-5.704|||||-1.704|-1.704|-0.005|28.78|28.78||3201761.8667|128.292|70915|||||||||||||43.5|1|2|-0.145|-0.755|1.157|0.007||||0.545||34.26|16.07
new_0222_0720|CMMB|202106|68.835|66.92||0.635||2.479|2.159|0.32||68.039|-28.169||||-17.0186||||3.1862|||||0.1911|1.915|0.472||||2|-0.8017||32.5897|10.8133||-0.26|1.446|11.3978||227.9561|||-0.26|-13.428|||-6.779|||||-2.77|-2.77|-0.017|19.21|19.21|149.8662|533865.2333|-13.2299|21785|||||-0.115||88.6957||-0.013||||43.5|1|2|-0.035|-0.075|1.307|0.007||||0.635||16.31|14.67
new_0222_0720|CMMB|202109|65.842|64.268||0.593||1.928|1.63|0.298||65.512|-31.137||||-5.9033||||1.9277|||||0.1761|1.574|0.481||||3|1.2853||29.9484|11.3978||-0.26|1.404|11.3978||227.9561|||-0.26|0.072|||-8.666|||||-2.968|-2.968|-0.077|11.95|11.95|62.0196|107698.9667|-39.2544|20076|||||-0.015||13.3333||-0.013||||43.5|1|2|-0.035|-0.075|1.487|0.009||||0.593||9.81|9.25
new_0222_0720|CMMB|202112|||||||||||||||-1.3704||||1.2008|||||0.236||||||1|0.0936||29.9698||||||||||||||||||||||7.05|7.05|14.3975|168249.9667|-75.0723|26903|||||-0.1033||||||||35|1|3|-0.3533|-0.4133||||||||5.22|3.86
new_0222_0720|CMMB|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.1033|||||||||||||||||||||
new_0222_0720|CMMB|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.1067|||||||||||||||||||||
new_0222_0720|CMMB|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.1067|||||||||||||||||||||
new_0222_0720|CMMB|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.11|||||||||||||||||||||